Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 2Withdrawn 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1Gynecologic 1

Conditions

Breast Neoplasms 77Stomach Neoplasms 14Neoplasms 8Neoplasm Metastasis 8HER2-positive Breast Cancer 4Esophageal Neoplasms 4Colorectal Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Brain Neoplasms 4Inflammatory Breast Neoplasms 3Breast Neoplasms, Male 3Triple Negative Breast Neoplasms 2Recurrence 2Ovarian Neoplasms 2Cardiotoxicity 2Urologic Neoplasms 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Solid Tumor 1Salivary Gland Neoplasms 1Rectal Neoplasms 1Pancreatic Neoplasms 1Neoplastic Cells, Circulating 1Myeloproliferative Disorders 1Mycosis Fungoides 1Multiple Myeloma 1Meningeal Neoplasms 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell, Marginal Zone 1

Interventions

Dexamethasone 29Cyclophosphamide 21Rituximab 17Cytarabine 16Bortezomib 13Gemcitabine 12fludarabine 11Methotrexate 11Lenalidomide 10Filgrastim 10Vincristine 9Etoposide 9pomalidomide 8pembrolizumab 8Paclitaxel 8Azacitidine 8venetoclax 7carfilzomib 7Doxorubicin 7Docetaxel 7Cyclosporine 7Calcium Dobesilate 7Antilymphocyte Serum 7fludarabine phosphate 6Topotecan 6Temozolomide 6Radiotherapy 6Peripheral Blood Stem Cell Transplantation 6Mitoxantrone 6daratumumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Recurrence × Trastuzumab × Clear all
NCT00724360 2013-10-07

Trastuzumab for HER2 Positive Relapsed/Refractory B-Acute Lymphoblastic Leukemia (B-ALL)

Nantes University Hospital

Phase 2 Terminated
15 enrolled
Other hematologic neoplasm

Leukemia, Recurrence

NCT00189579 2007-08-17

Addition of Herceptin to a Carboplatin-Paclitaxel Regimen in Patients With Ovarian Cancer

ARCAGY/ GINECO GROUP

Phase 2 Terminated
45 enrolled
Gynecologic

Ovarian Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡